[
    [
        {
            "time": "2018-05-22",
            "original_text": "公告精选：金龙机电控股股东部分质押股份存在平仓风险；凯迪生态大股东所持28.53%股份被轮候冻结 股票质押异常",
            "features": {
                "keywords": [
                    "金龙机电",
                    "控股股东",
                    "质押股份",
                    "平仓风险",
                    "凯迪生态",
                    "股份冻结",
                    "股票质押"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "电子设备",
                    "环保"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "公告精选：金龙机电控股股东部分质押股份存在平仓风险；凯迪生态大股东所持28.53%股份被轮候冻结 股票质押异常",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-21",
            "original_text": "复星医药：子公司草酸艾司西酞普兰片通过仿制药一致性评价",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "草酸艾司西酞普兰片",
                    "仿制药",
                    "一致性评价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：子公司草酸艾司西酞普兰片通过仿制药一致性评价",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-05-22",
            "original_text": "“入摩”名单重磅发布 医药股或成最大赢家",
            "features": {
                "keywords": [
                    "入摩",
                    "医药股",
                    "赢家"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "“入摩”名单重磅发布 医药股或成最大赢家",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-22",
            "original_text": "22家药企开医院：人福、益佰、康美、华润…",
            "features": {
                "keywords": [
                    "药企",
                    "医院",
                    "人福",
                    "益佰",
                    "康美",
                    "华润"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "22家药企开医院：人福、益佰、康美、华润…",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-22",
            "original_text": "QFII早锁定47只“入摩”股 医药股数量最多",
            "features": {
                "keywords": [
                    "QFII",
                    "入摩",
                    "医药股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "QFII早锁定47只“入摩”股 医药股数量最多",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-22",
            "original_text": "医药行业每周观点:从三个方向继续深挖医药投资机会,重点推荐万孚生物、葵花药业等优质标的",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资机会",
                    "万孚生物",
                    "葵花药业"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业每周观点:从三个方向继续深挖医药投资机会,重点推荐万孚生物、葵花药业等优质标的",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]